Cargando…

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan

INTRODUCTION: Comparison of the effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors (TKIs) would improve patients’ clinical benefits and save costs. Using real-world data, this study attempted to directly compare the effectiveness and cost-effectiveness of first-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Szu-Chun, Lai, Wu-Wei, Hsu, Jason C., Su, Wu-Chou, Wang, Jung-Der
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141611/ https://www.ncbi.nlm.nih.gov/pubmed/32267879 http://dx.doi.org/10.1371/journal.pone.0231413

Ejemplares similares

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
por: Su, Po-Lan, et al.
Publicado: (2018)

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
por: Xu, Jianlin, et al.
Publicado: (2016)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
por: Arrieta, Oscar, et al.
Publicado: (2020)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Hondelink, Liesbeth M., et al.
Publicado: (2021)

Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence
por: Chang, Huang‐Chih, et al.
Publicado: (2023)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Real‐world outcomes among patients with EGFR‐mutated non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first‐line setting
por: Apple, Jon, et al.
Publicado: (2023)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
por: Chang, Huang‐Chih, et al.
Publicado: (2023)

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
por: Su, Po‐Lan, et al.
Publicado: (2020)

EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan
por: Chung, Ching-Hu
Publicado: (2019)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study
por: Munawar, Kiran, et al.
Publicado: (2023)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada
por: Qureshi, Samia, et al.
Publicado: (2022)

The Protective Effects of Influenza Vaccination in Elderly Patients with Breast Cancer in Taiwan: A Real-World Evidence-Based Study
por: Wu, Szu-Yuan, et al.
Publicado: (2022)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
por: Gandhi, Jeet, et al.
Publicado: (2009)

Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
por: Boonsri, Boonyakorn, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
por: Choi, Jin-Hyuk, et al.
Publicado: (2022)

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
por: Su, Vincent Yi-Fong, et al.
Publicado: (2020)

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
por: Ma, Jun, et al.
Publicado: (2023)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer
por: Yang, Szu‐Chun, et al.
Publicado: (2023)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
por: Sung, Mike R., et al.
Publicado: (2021)

Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan
por: Tsai, Yu-Fen, et al.
Publicado: (2018)

Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants
por: Xie, Xianhe, et al.
Publicado: (2020)

Comparative effectiveness of first-line antihypertensive drug classes on the maintenance of estimated glomerular filtration rate (eGFR) in real world primary care
por: Gao, Qiao, et al.
Publicado: (2023)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
por: Chen, Yongshun, et al.
Publicado: (2016)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_koeucdqnsm030tktpmb5ra7vjh